|
1
|
Jänne PA, Yang JC, Kim DW, Planchard D,
Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291
in EGFR inhibitor-resistant non-small cell lung cancer. N Engl J
Med. 372:1689–1699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sequist LV, Yang JC, Yamamoto N, O'Byrne
K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al:
Phase III study of afatinib or cisplatin plus pemetrexed in
patients with metastatic lung adenocarcinoma with EGFR mutations. J
Clin Oncol. 31:3327–3334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hotta K, Kiura K, Takigawa N, Yoshioka H,
Harita S, Kuyama S, Yonei T, Fujiwara K, Maeda T, Aoe K, et al:
Comparison of the incidence and pattern of interstitial lung
disease during erlotinib and gefitinib treatment in Japanese
Patients with non-small cell lung cancer: The Okayama Lung Cancer
Study Group experience. J Thorac Oncol. 5:179–184. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ahn MJ, Yang J, Yu H, Saka H, Ramalingam
S, Goto K, Kim SW, Yang L, Walding A and Oxnard GR: 136O:
Osimertinib combined with durvalumab in EGFR-mutant non-small cell
lung cancer: Results from the TATTON phase Ib trial. J Thorac
Oncol. 11:S1152016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gibbons DL, Chow LQ, Kim DW, Kim SW, Yeh
T, Song X, Jiang H, Taylor R, Karakunnel J and Creelan B: 570
Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a
human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody,
combined with gefitinib (G): A phase I expansion in TKI-naïve
patients (pts) with EGFR mutant NSCLC. J Thorac Oncol. 11:S792016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gettinger SN, Horn L, Gandhi L, Spigel DR,
Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman
DM, et al: Overall survival and long-term safety of nivolumab
(anti-programmed death 1 Antibody, BMS-936558, ONO-4538) in
patients with previously treated advanced non-small-cell lung
cancer. J Clin Oncol. 33:2004–2012. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee CK, Man J, Lord S, Links M, Gebski V,
Mok T and Yang JC: Checkpoint inhibitors in metastatic EGFR-mutated
non-small cell lung cancer-A meta-analysis. J Thorac Oncol.
12:403–407. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang T, Xie J, Arai S, Wang L, Shi X, Shi
N, Ma F, Chen S, Huang L, Yang L, et al: The efficacy and safety of
anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory
cancers: A meta-analysis. Oncotarget. 7:73068–73079.
2016.PubMed/NCBI
|
